Citations

Clear

912 citation(s) found for "Yu, Caroline".

Learning Curves and Complexity Evolution in Robotic Liver Surgery
Kuemmerli, Christoph , Hess, Gabriel Fridolin , Billeter, Adrian T. , Benedetto, Fabrizio Di , Odorizzi, Roberta, Sucandy, Iswanto , Aegerter, Noa L. E., Berchtold, Caroline , Bernardi, L. , Cristaudi, Alessandra , Balzano, E , Koh, Ye-Xin, Lin, Charles Chung-Wei, Fukumori, Daisuke , Tschuor, Christoph , White, Steve, Kroge, P Von, Heumann, Asmus , Meyere, Céline De, D’hondt, M, Haak, Fabian, Stättner, Stefan, Primavesi, Florian, Morgül, Haluk , Andreou, A, Ratti, F, Esquer, Ignacio Sánchez, Robles-Campos, Ricardo, Lopez-Lopez, Victor, Wakabayashi, Go , Nebbia, Martina, Rahbari, Nuh N., Ferretti, Stefano, Ettore, Giuseppe , Croner, RS , Dong, Y, Starlinger, P, Nickel, F, Müller, Beat P., Hess, Gabriel F , Guidetti, Cristiano , di Benedetto, Fabrizio , Sucandy, Iswanto , Aegerter, Noa L E , Berchtold, Caroline , Bernardi, Lorenzo , Cristaudi, Alessandra , Balzano, Emanuele , Ghinolfi, Davide , Goh, Brian K P , Fukumori, Daisuke , Tschuor, Christoph , Pandanaboyana, Sanjay , De Meyere, Celine , Seehofer, Daniel , Esquer, Ignacio Sánchez , Müller, Philip C , Koh, Ye-Xin , Lin, Charles Chung-Wei, Tschuor, Christoph , Kroge, Philipp H. von , D’Hondt, Mathieu , Haak, Fabian , Stättner, Stefan , Primavesi, Florian , Ratti, Francesca , Robles-Campos, Ricardo, López‐López, Víctor , Wakabayashi, Taiga , Nebbia, Martina , Gilg, Stefan , Birgin, Emrullah , Ferretti, Stefano , Ettore, Giuseppe Maria, Rahimli, Mirhasan , Nickel, Felix , Müller-Stich, Beat Peter

Mayo Clinic

Annals of Surgery | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000007123 | PMID 42307103 Get It

Objective: To evaluate the institutional learning curve of robotic liver resection (RLR), its association with surgical complexity and outcomes in an international multicenter cohort. Summary of Background Data: RLR is increasingly adopted worldwide, but the dynamics of the learning process and its impact on surgical outcomes remain poorly defined. Methods: This international, multicenter, retrospective cohort study included consecutive patients who underwent RLR between 06/2013 and 12/2024 across 22 expert centers. Based on the first 150 cases at each center, three phases were used to define the learning curve: operative time for competency, major complications for proficiency, and textbook outcome for mastery. Risk-adjusted generalized additive models were used to assess the learning process. Benchmark performance was compared to international reference values. Results: Among 2,331 patients, the most common indications were hepatocellular carcinoma (36%), benign lesions (23%) and colorectal liver metastases (21%). Operative time decreased after achieving competency (case #62), from 240 to 220 minutes ( P <0.001). Major morbidity reached a plateau during the proficiency phase (cases #63–138; 9% vs. 11%, P =0.144), while progression to mastery (cases #139–150) was associated with a higher rate of textbook outcome (76% vs. 87%, P =0.021). In contrast, conversion (5.1% vs. 4.9% vs. 2%), bile leak (4.0% vs. 5.3% vs. 3.8%), and 90-day mortality (0.7% vs. 0.9% vs. 0.9%) remained low and stable across all learning phases. Importantly, benchmark criteria for operative time, hospital stay, and textbook outcome were met across all complexity groups, including during the early learning phase. Conclusions: Robotic liver surgery shows progressive outcome improvement with early achievement of benchmark-level results and stable performance across increasing complexity. These findings indicate that, in experienced centers, RLR can be safely implemented and integrated into clinical practice, supporting its key role in modern hepatobiliary surgery.
Sexually dimorphic mediation of experimental post-traumatic headache by orexin receptor signaling
Vizin, Robson Cristiano Lillo , Anderson, Trent, Porreca, Frank , Anderson, Trent , Lee, Grace J. , Lillo Vizin, Robson C , Kopruszinski, Caroline , Porreca, Frank , Kopruszinski, Caroline Machado , Lee, Grace , Moutal, Aubin , Dodick, David W. , Schwedt, Todd J. , Navratilova, Edita

Mayo Clinic

Pain | June 16, 2026 | Volume: 167 | Issue: 9 | Pages: 2156-2170

10.1097/j.pain.0000000000004035 | PMID 42302125 Get It

Abstract Mild traumatic brain injury (mTBI) commonly induces transient acute (APTH) or persistent (PPTH) post-traumatic headache (PTH) that often resembles migraine. As orexin B sensitizes male but not female murine, nonhuman primate, and human dorsal root ganglion neurons and supradural orexin B/orexin receptor 2 (OX2R) signaling elicits migraine-like pain in naïve male, but not female, mice we explored possible sexually dimorphic contributions of orexin B/OX2R to PTH. In mice of both sexes, mTBI-induced transient cephalic allodynia, a surrogate measure of APTH. After APTH resolution, allodynia was reinstated by exposure to normally innocuous stress or by inhalational delivery of a subthreshold concentration of umbellulone, a TRPA1 agonist, suggesting the expression of PPTH. In contrast to these nonselective stimuli, subthreshold supradural orexin B induced PPTH only in male mTBI mice. Intranasal delivery of a CRISPR/Cas9 plasmid to edit trigeminal OX2R expression prevented APTH and development of PPTH selectively in male mTBI mice. Daily oral suvorexant, a dual orexin receptor antagonist (DORA), beginning immediately after mTBI, prevented APTH as well as PPTH. Critically, starting suvorexant treatment after resolution of APTH also prevented stress- or umbellulone-induced PPTH. EEG/EMG-defined sleep architecture or immobility-defined sleep was not disrupted in this mTBI model suggesting that suvorexant benefits are unlikely related to sleep modulation. Our findings reveal a male-specific mechanism of PTH maintained by orexin B/OX2R signaling and suggest that approved DORAs may be beneficial in treating APTH and preventing transition to PPTH in men. Importantly, DORAs may also be effective in men with established PPTH.
Delayed graft function and long-term outcomes after deceased donor kidney transplantation: insights from mate-kidney analysis
Valencia, Oscar A. Garcia, Alrifai, Ahmed, Mahgoub, Mohammed, Mour, Girish, Smith, Byron, Bentall, Andrew J., Issa, Naim , Riad, Samy, Garcia Valencia, Oscar A, Alrifai, Ahmed Zeen Alabedeen, Mahgoub, Mohammed Y, Issa, Naim S, Cortez, Alexander R. , Valencia, Oscar A. Garcia , Mour, Girish , Bentall, Andrew , Jadlowiec, Caroline C. , Amer, Hatem , Riad, Samy

Mayo Clinic

Transplant International | June 16, 2026 | Volume: 39 | Issue: No issue available | Pages: No page available

10.3389/ti.2026.16526 | PMID 42382229 Get It

Delayed graft function (DGF) is a frequent complication after deceased donor kidney transplantation, yet its long-term impact remains understudied. Heterogeneous populations, short follow-up, and inadequate control of donor-related factors have limited prior studies. Using the Scientific Registry of Transplant Recipients (2005–2024), we evaluated the association between DGF and long-term graft outcomes, including a mate-kidney (same donor, discordant DGF status) analysis to isolate its independent effect. We identified 103,678 dialysis-dependent deceased donor kidney recipients maintained on tacrolimus and mycophenolate. Mixed-effects Cox models, adjusted for donor, recipient, immunologic, and procurement factors. DGF occurred in 30.1% of recipients and was associated with increased death-censored graft failure (HR 1.40; 95% CI 1.33–1.47) and overall graft failure (HR 1.27; 95% CI 1.23–1.31). DGF recipients had higher rejection rates at 6 (6.0% vs. 4.7%) and 12 months (8.9% vs. 7.3%), longer hospital stay, and higher 1-year rehospitalization. In the mate-kidney analysis (6,818 donors), DGF remained strongly associated with death-censored graft failure (HR 1.58; 95% CI 1.39–1.80) and overall graft failure (HR 1.35; 95% CI 1.25–1.46), confirming the independent effect of DGF. DGF is a strong predictor of adverse long-term outcomes irrespective of rejection and warrants targeted prevention strategies and intensified follow-up.
Trajectories of brain structure and function in young adult carriers of genetic frontotemporal dementia variants
So, Isis , Staffaroni, Adam M. , Coleman, Kristy , Bouzigues, Arabella , Ferry‐Bolder, Eve , Cullen, Eva , Russell, Lucy L. , Foster, Phoebe H. , Farley, Sophie , Thompson, Alexander, Ber, Isabelle Le , Körtvelyessy, Péter , Schroeter, M., Uzelac, Željko , Kruger, Johanna S. W. , Langheinrich, Tobias , Ducharme, Simon , Santana, Isabel J., Tartaglia, Carmela, Mendonca, Alexandre de, Morenoizco, Fermin, Brushaber, Danielle, Considine, Ciaran , Faber, Kelley, Fagan, Anne, Fields, Julie, Foroud, Tatiana, Forsberg, Leah K. , Geschwind, Daniel, Heuer, Hilary W. , Huang, Eric, Kantarci, Kejal, Kolander, Tyler , Lago, Argentina Lario , Lavigne, Shannon B., Mester, Carly , Molden, Joie, Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eilana, Rankin, Katherine P., Rascovsky, Katya, Rhoads, Kristoffer , Weintraub, Sandra, Wong, Bonnie, Boxer, Adam L. , Rosen, Howard J. , Lee, Suzee E. , Lombardi, Jolina , Staffaroni, Adam M , Coleman, Kristy K L , Bouzigues, Arabella , Ferry-Bolder, Eve , Cullen, Eva , Russell, Lucy L , Foster, Phoebe H , Farley, Sophie , Convery, Rhian , Van Swieten, John C , Jiskoot, Lize C , Seelaar, Harro , Galimberti, Daniela , Vandenberghe, Rik , Laforce, Robert , Bruffaerts, Rose , Bertoux, Maxime , Lebouvier, Thibaud , Solje, Eino , Xiong, Chengjie , di Fede, Giuseppe , Le Ber, Isabelle , Migliaccio, Raffaella Lara , Körtvélyessy, Peter , Logroscino, Giancarlo , Otto, Markus , Uzelac, Zeljko , Illán-Gala, Ignacio , Krüger, Johanna , Nacmias, Benedetta , Gerhard, Alexander , Langheinrich, Tobias , Ducharme, Simon , Masellis, Mario , Rowe, James B , Graff, Caroline , Synofzik, Matthis , Borroni, Barbara , Sánchez-Valle, Raquel , Considine, Ciaran M , Forsberg, Leah K , Gendron, Tania F , Heuer, Hilary W , Huang, Eric , Kolander, Tyler , Mester, Carly , Petrucelli, Leonard , Rademakers, Rosa , Vandebergh, Marijne , Boeve, Brad , Boxer, Adam , Rosen, Howard J , Lee, Suzee E , Rohrer, Jonathan D , Finger, Elizabeth C. , Lombardi, Jolina , Swieten, John C. van , Jiskoot, Lize C. , Seelaar, Harro , Galimberti, Daniela , Vandenberghe, Rik , Laforce, Robert , Lebouvier, Thibaud , Xiong, Chengjie , Thompson, Alexander G. , Logroscino, Giancarlo , Otto, Markus , Illán‐Gala, Ignacio , Nacmias, Benedetta , Tartaglia, Carmela M., de Mendonça, Alexandre , Rowe, James B. , Graff, Caroline , Moreno, Fermín , Synofzik, Matthis , Borroni, Barbara , Sánchez‐Valle, Raquel , Brushaber, Danielle , Fagan, Anne M. , Gendron, Tania F. , Geschwind, Daniel, Kantarci, Kejal , Ramos, Eliana Marisa , Rankin, Katherine P. , Vandebergh, Marijne , Weıntraub, Sandra , Boeve, Bradley F. , Rohrer, Jonathan D.

Mayo Clinic

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.08.26355165 | PMID 42326777 Get It

ABSTRACT Background and Objectives Converging evidence hints at neurodevelopmental effects in genetic frontotemporal degeneration (FTD). In cross-sectional studies, for some genes, young adult FTD variant carriers show differences in brain volumes and cognition compared to familial non-carriers. However, longitudinal trajectories may more sensitively capture FTD-related neurodevelopmental vs. neurodegenerative changes than cross-sectional approaches. This study examined longitudinal trajectories of brain volumes, executive function, and plasma biomarkers in young adult carriers compared to familial non-carriers, as measures of neurodevelopmental and neurodegenerative outcomes of FTD-causing variants. Methods This longitudinal cohort study comprised participants, aged 18-30 years, from the FTD Prevention Initiative across Europe, Canada, and the USA. Genetic groups included C9orf72 (47%), MAPT (30%), and GRN (23%). Linear mixed-effects models were computed to assess longitudinal outcomes across age between groups, controlling for sex, scanner (for brain volumes), and education (for executive function); random effects accounted for between-subject variability nested within family membership. Results Variant carriers ( n =147) and familial non-carriers ( n =113) did not differ in age (mean±SD, 25.9±3.2 years), sex (53% female), or number of visits (2.1±1.7). Young adult C9orf72 repeat expansion carriers exhibited smaller thalamic volumes than non-carriers at the reference age of 26 years ( b =-982.8mm 3 , SE=317.0, p= 0.0046, f 2 =0.32), with relatively stable trajectories across ages 18-30 (i.e., no change over time). Trajectories of rostral anterior cingulate volumes differed in C9orf72 carriers and non-carriers across age, where carriers showed relatively stable trajectories and non-carriers showed age-appropriate declines ( b =64.4mm 3 , SE=29.9, p= 0.035, f 2 =0.07). For MAPT and GRN , there were little to no differences in total brain, cortical, or subcortical volumes between groups and over time. No longitudinal differences were observed between carriers and non-carriers in executive function, or plasma NfL or GFAP for any genetic group. Discussion C9orf72 repeat expansions were linked to smaller average thalamic volumes and stable trajectories between ages 18 to 30, supporting potential neurodevelopmental origins. The modest evidence supporting an absence of difference in neurodegenerative biomarkers and executive function suggests minimal early neurodegeneration and functional preservation in young adulthood.
Diagnostic Accuracy of Multimodal LLMs in Differentiating Epileptic from Non-epileptic Events in Smartphone Recorded Videos (P2-11.005)
Patel, Anshum , Vallamchetla, Sai Krishna , Safa, Adrian , Tatit, Caroline, Kissinger‐Knox, Alicia, Roberts, Mark, Bestic, Olivia, Tatum, William, Freund, Brin, Tatit, Caroline P., Kissinger-Knox, Alicia M. , Tatum, William, Freund, Brin

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215770 Get It

Continuous integral debridement: optimising wound bed preparation through the cleanse, debride, cleanse and dress cycle
Dowsett, Caroline, Gonçalves, Viviana , Melin, M Mark, Moodley, Prashini , Stuermer, Ewa Klara , Maella, Natalia, Howaldt, Monira Nou, Probst, Sebastian, Woo, Kevin, Mayer, Dieter , Atkin, Leanne , Dowsett, Caroline , Kalan, Lindsay , Pastar, Irena , Melin, M. Mark , Stuermer, Ewa K. , Maella-Rius, Natalia , Nou, Monira , Probst, Sebastian

Mayo Clinic

Journal of Wound Care | June 10, 2026 | Volume: 35 | Issue: Sup6d | Pages: No page available

10.12968/jowc.2026.0275 | PMID 42267756 Get It

In 2024, the Journal of Wound Care ( JWC ) published best-practice guidance on wound debridement. This introduced the concept of integral debridement, defined as the combined use of complementary debridement methods on the same wound to optimise healing outcomes. This typically involves combining less invasive approaches, such as autolytic debridement, with more active adjunctive methods, including mechanical and/or sharp debridement. In 2026, JWC convened an expert panel to explore how this concept can be effectively implemented in non-specialist settings. The panel concluded that debridement is most effective when applied repeatedly throughout the healing process and introduced the concept of continuous integral debridement (CID), a cyclical four-step approach comprising cleanse, debride, cleanse and dress (CDCD). The panel propose that, when performed regularly, this will help disrupt microbial and non-microbial barriers to healing and maintain a clean wound environment. The panel consider that CID is compatible with established frameworks, such as TIME/TIMERS and the International Wound Infection Institute wound infection continuum, and complements antibiofilm strategies, including Wound Hygiene. This document provides practical guidance for integrating CID into routine wound care across all clinical settings, including recommendations on cleansing solutions, debridement methods and dressing selection, with the aim of supporting evidence-based practice and improving patient outcomes.
Determinants of Long‐Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis
Steinhardt, Maximilian J., Hegenbart, Ute , Hellou, Tamer , Oubari, Sara, Roussel, Murielle , Schwotzer, Rahel , Buadi, Francis, Dingli, David, Kourelis, Taxiarchis, Zanwar, Saurabh , Rieger, Max J., Morbach, Caroline, Cejka, Vladimir , Störk, Stefan, Einsele, Hermann, Kumar, Shaji, Gertz, MA, Carpinteiro, Alexander , Kortum, K. Martin, Dispenzieri, Angela, Steinhardt, Maximilian , Steinhardt, Maximilian , Zanwar, Saurabh S , Rieger, Max J , Cejka, Vladimir , Gertz, Morie A , Muchtar, E , Hegenbart, Ute , Roussel, Murielle , Buadi, Francis K. , Dingli, David , Binder, Moritz , Kourelis, Taxiarchis , Morbach, Caroline , Gerber, B. , Störk, Stefan , Kumar, Shaji, Gertz, Morie A. , Kortüm, Martin , Muchtar, Eli , Dispenzieri, Angela , Schönland, Stefan

Mayo Clinic

American Journal of Hematology | June 8, 2026 | Volume: 101 | Issue: 8 | Pages: 1903-1914

10.1002/ajh.70371 | PMID 42252535 Get It

ABSTRACT High dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain amyloidosis, but its incremental benefit in the era of effective standard intensity therapy is unknown. We retrospectively analyzed 475 transplant‐eligible patients who completed standard intensity treatment with or without HDM within 12 months at six centers in Europe and the United States between 2010 and 2024 to evaluate outcomes by baseline risk factors, hematologic response, and receipt of HDM. Death was an equally competing risk after the 12‐month landmark chosen to address early non‐proportional hazards and to ensure completion of first‐line therapy. BMPC > 20% was associated with inferior outcomes (HR 1.7), and gain/amp 1q with shorter TTP (HR 2.15), whereas other high‐risk FISH abnormalities were not. In multivariable models, VGPR/CR after standard intensity therapy was associated with longer TTP (HR 0.49/0.29), while gain/amp 1q remained independently associated with shorter TTP (HR 2.18). Receipt of daratumumab and HDM were associated with longer TTP (HR 0.44/0.61). HDM benefited patients who had not achieved CR after standard intensity therapy (mTTP 21.0 vs. 5.7 months without HDM), whereas patients already in CR did not benefit. Higher BMPC at diagnosis was associated with earlier progression in patients not receiving HDM (HR 1.9 for 5%–20% and 4.09 for > 20%), a risk attenuated in the HDM cohort. Gain/amp 1q remained associated with shorter TTP regardless of HDM exposure. These findings support a selective role for HDM, primarily benefiting patients with residual disease after standard intensity therapy or higher BMPC burden at diagnosis.
Clinical Practice of Indocyanine Green Fluorescence Imaging in Robotic Liver Surgery – A Global Expert Survey
Aegerter, N L E, Kuemmerli, C, Billeter, A T, Berchtold, C, Nickel, F, Guidetti, C, Wakabayashi, T, Sucandy, I, Goh, B K, D’hondt, M, Marques, H Pinto, Eden, J, Dutkowski, P, Hawksworth, J, Starlinger, P, Müller, B P, Müller, P C, Aegerter, Noa L E , Kuemmerli, Christoph , Billeter, Adrian T. , Berchtold, Caroline , Nickel, Felix , Guidetti, Cristiano , Sucandy, Iswanto , Goh, Brian K P , D’Hondt, Mathieu , Eden, Janina , Dutkowski, Philipp , Hawksworth, Jason Solomon , Müller, P C

Mayo Clinic

British Journal of Surgery | June 3, 2026 | Volume: 113 | Issue: Supplement_5 | Pages: No page available

10.1093/bjs/znag055.029 Get It

Abstract Background Indocyanine green (ICG) fluorescence imaging is increasingly incorporated into robotic liver resections (RLR), yet clinical practice regarding timing, dosage, and staining techniques is divergent. Aims This international expert survey aimed to characterize current practices for ICG in RLR. Methods Experts in RLR were invited to participate based on surgical volume (experience of 50 RLR and 30 annual RLR). A 74-item questionnaire was developed following a literature search and reviewed by a steering committee. The survey addressed indications, timing, dosage, imaging technology, benefits, limitations, training, and future directions of ICG use. Responses collected between September and October 2025 were analyzed. Results Seventy experts from 19 countries completed the survey, corresponding to an 88% response rate. Centers performed a median of 180 annual liver resections, including 55 RLR. Most experts used ICG (96%) during RLR. Anatomical demarcation (91%), tumor localization (60%), and biliary anatomy assessment (60%) were the most frequent indications. 60% of experts use preoperative ICG, while intraoperative ICG is mainly administered for demarcation (67%) and biliary tract visualization (40%). Considerable heterogeneity exists in dosage, timing, and staining techniques, particularly in cirrhotic livers and for tumor localization. Only half of the experts had standard operating procedures, whereas 64% expressed the need for a higher degree of standardization. Reported benefits of ICG use included improved anatomical orientation, margin assessment, lesion detection, and support during complex resections. Perceived limitations included background fluorescence, tissue penetration and variable staining in diseased parenchyma. 80% anticipated improved outcomes with combined ICG and three-dimensional image-guidance. Conclusion ICG fluorescence is widely used in RLR and is an important cornerstone for precision-guided robotic liver surgery. Standardized clinical practice guidelines, structured training, and technological improvements in imaging and navigation systems are claimed to optimize its clinical use.
APOE3-Christchurch variant enhances neurovascular support functions of iPSC-derived mesenchymal stromal cells
Martinez, Paula J. Rodriguez, Yslas, Aria R., Inoue, Yasuteru , Parsons, Tammee M., Baker, Samantha K., Lü, Wenyan, Raulin, Ana‐Caroline , Kanekiyo, Takahisa , Rodriguez Martinez, Paula J, Raulin, Ana-Caroline , Yslas, Aria R.

Mayo Clinic

Frontiers in Molecular Biosciences | June 1, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fmolb.2026.1778856 | PMID 42306774 Get It

Aging and neurodegenerative disorders like Alzheimer’s Disease (AD) are associated with progressive dysfunction of the blood-brain barrier (BBB) and neurovascular unit (NVU), contributing to impaired vascular integrity and neuronal vulnerability. Apolipoprotein E (APOE) is a key regulator of neurovascular function, and the rare APOE3-R136S “Christchurch” variant ( APOE3Ch ) confers protection against AD. Mesenchymal stromal cells (MSCs) represent a promising cell-based therapy for the treatment of neurodegenerative diseases due to their paracrine effect exerted on vascular and neural cells. To investigate how APOE3Ch influences MSC-mediated neurovascular support, we used isogenic iPSC-derived MSCs (iMSCs) with homozygous APOE3Ch or APOE3 . We found that APOE3Ch iMSCs have stronger immunosuppressive effect on LPS-induced NFκB activation of THP1 cells. APOE3Ch iMSCs also enhanced endothelial barrier resistance and angiogenic capacity compared to APOE3 iMSCs when directly co-cultured with endothelial cells. In addition, conditioned medium from APOE3Ch iMSCs promoted neurite outgrowth more efficiently than that from APOE3 iMSCs. Metabolic profiling revealed differences between APOE3Ch and APOE3 iMSCs, suggesting altered metabolic resilience. Together, these findings demonstrate that iMSCs support vascular and neuronal function through paracrine mechanisms and suggest that APOE3Ch variant improves specific aspects of MSC-mediated neurovascular support. This work highlights the potential of combining MSC-based therapies with protective APOE variants to target BBB and NVU dysfunction in aging and neurodegeneration.